Loading...
•
Sep 30, 2024
Third Harmonic Q3 2024 Earnings Report
Announced third quarter 2024 financial results.
Key Takeaways
Third Harmonic Bio reported a net loss of $13.8 million for the third quarter of 2024, with cash and cash equivalents totaling $296.1 million as of September 30, 2024.
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25.
Cash and cash equivalents totaled $296.1 million as of September 30, 2024.
R&D expenses increased to $11.3 million for the three months ended September 30, 2024, from $6.0 million for the same period in 2023.
Net loss for the three months ended September 30, 2024, increased to $13.8 million from a net loss of $7.3 million for the same period in 2023.
Forward Guidance
Third Harmonic Bio believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...